Altimmune falls after posting quarterly revenue below estimates
05/03/2026 17:41
** Shares of drug developer Altimmune ALT.O fall 8.9% to $3.89 ** Co reports Q4 loss of 27 cents/shr vs analysts' average estimate of 24 cents/shr - data compiled by LSEG ** Says Q4 revenue was $26,000 vs estimate of $700,000 ** Shares down 50% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)